Harbour Investments’s Tvardi Therapeutics TVRD Stock Holding History

Harbour Investments’s Portfolio TVRD Stock Details TVRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$29	Hold	15	–	–	﹤0.01%	4706
2026 Q1	$48	Hold	15	–	–	﹤0.01%	4582
2025 Q4	$65	Hold	15	–	–	﹤0.01%	3771
2025 Q3	$585	Buy	15 +1	+7%	+$28	﹤0.01%	3490
2025 Q2	$327	Hold	14	–	–	﹤0.01%	3427
2025 Q1	$213	Buy	+14	New	+$211	﹤0.01%	3427
2024 Q4	–	Sell	-15	Closed	-$162	–	3597
2024 Q3	$162	Hold	15	–	–	﹤0.01%	3289
2024 Q2	$135	Hold	15	–	–	﹤0.01%	3190
2024 Q1	$478	Buy	15 +6	+67%	+$156	﹤0.01%	3028
2023 Q4	$237	Hold	9	–	–	﹤0.01%	3003
2023 Q3	$536	Buy	9 +2	+29%	+$188	﹤0.01%	2797
2023 Q2	$708	Hold	7	–	–	﹤0.01%	2756
2023 Q1	$1.23K	Hold	7	–	–	﹤0.01%	2653
2022 Q4	$2.69K	Hold	7	–	–	﹤0.01%	2443
2022 Q3	$2K	Hold	7	–	–	﹤0.01%	2501
2022 Q2	$2K	Buy	+7	New	+$2.46K	﹤0.01%	2501
2021 Q4	$3K	Sell	7 -62	-90%	-$31.2K	﹤0.01%	2354
2021 Q3	$38K	Sell	69 -7	-9%	-$3.51K	﹤0.01%	1946
2021 Q2	$39K	Buy	76 +1	+1%	+$634	﹤0.01%	1958
2021 Q1	$59K	Buy	+75	New	+$51.3K	﹤0.01%	1600

Other funds holding TVRD

SPC

Slate Path Capital New York $7.22B AUM 110.75% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AFG

American Financial Group Cincinnati, Ohio $284M AUM 12.01% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

SAM

Silvercrest Asset Management New York $15.3B AUM 40.56% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

DWAM

Duncan Williams Asset Management Memphis, Tennessee $444M AUM 24.78% 1-Year Est. Return

Harbour Investments's TVRD Position: Q2 2026 in Review

Harbour Investments held its Tvardi Therapeutics (TVRD) position steady in Q2 2026 at 15 shares worth $29. The position accounts for ﹤0.01% of the portfolio, ranked #4706.

Harbour Investments first reported a position in TVRD in Q1 2021 and has held it in 20 quarters since. The position peaked at $59K in Q1 2021. 58 funds tracked by Wall St. Rank hold TVRD as of Q2 2026.

Harbour Investments held 15 shares of Tvardi Therapeutics worth $29 as of Q2 2026.
Harbour Investments left its Tvardi Therapeutics share count unchanged in Q2 2026.
Tvardi Therapeutics made up ﹤0.01% of Harbour Investments's portfolio in Q2 2026, its #4706 holding.
Harbour Investments first reported a position in Tvardi Therapeutics in Q1 2021 and has held it in 20 quarters since.
Harbour Investments's Tvardi Therapeutics position peaked at $59K in Q1 2021.
58 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2026.

Based on Harbour Investments's 13F filing for Q2 2026, filed 12 Aug 2026.